http://orcid.org/0000-0001-9453-9688
References
- Khokha R, Murthy A, Weiss A. Metalloproteinases and their natural inhibitors in inflammation and immunity. Nat Rev Immunol 2013;13(9):649–665.
- Mishra HK, Ma J, Walcheck B. Ectodomain shedding by ADAM17: Its role in neutrophil recruitment and the impairment of this process during sepsis. Front Cell Infect Microbiol 2017;7:138. doi: 10.3389/fcimb.2017.00138.
- Takeda S. ADAM and ADAMTS family proteins and snake venom metalloproteinases: a structural overview. Toxins 2016;8(5):155. doi: 10.3390/toxins8050155.
- Gardiner EE, Arthur JF, Kahn ML, Berndt MC, Andrews RK. Regulation of platelet membrane levels of glycoprotein VI by a platelet-derived metalloproteinase. Blood 2004:104(12):3611–3617.
- Fong KP, Barry C, Tran AN, Traxler EA, Wannemacher KM, Tang H-Y, Speicher KD, Blair IA, Speicher DW, Grosser T, Brass LF. Deciphering the human platelet sheddome. Blood 2011;117(1):15–26.
- Andrews RK, Gardiner EE. Basic mechanisms of platelet receptor shedding. Platelets 2017; 28(4):319–324.
- Bender M, Stegner D, Nieswandt B. Model systems for platelet receptor shedding. Platelets 2017;28(4):325–332.
- Matthews AL, Noy PJ, Reyat JS, Tomlinson MG. Regulation of A disintegrin and metalloproteinase (ADAM) family sheddases ADAM10 and ADAM17: The emerging role of tetraspanins and rhomboids. Platelets; 2017;28(4):333–341.
- Atapattu L, Saha N, Chheang C, Eissman MF, Xu K, Vail ME, Hii L, Llerena C, Liu Z, Horvay K, Abud HE, Kusebauch U, Moritz RL, Ding B-S, Cao Z, Rafii S, Ernst M, Scott AM, Nikolov DB, Lackmann M, Janes PW. An activated form of ADAM10 is tumor selective and regulates cancer stem-like cells and tumor growth. J Exp Med 2016;213(9):1741–1757.
- Saftig P, Lichtenthaler SF. The alpha secretase ADAM10: A metalloprotease with multiple functions in the brain. Prog Neurobiol 2015;135:1–20.
- Gooz M. ADAM-17: the enzyme that does it all. Crit Rev Biochem Mol Biol 2010;45(2):146–169.
- Rossello A, Nuti E, Ferrini S, Fabbi M. Targeting ADAM17 Sheddase Activity in Cancer. Curr Drug Targets 2016;17(16):1908–1927.
- Rose-John S. ADAM17, shedding, TACE as therapeutic targets. Pharmacol Res 2013;71:19–22.
- Jackson HW, Defamie V, Waterhouse P, Khokha R. TIMPs: versatile extracellular regulators in cancer. Nat Rev Cancer 2017;17(1):38–53.
- Tauro M, McGuire J, Lynch CC. New approaches to selectively target cancer-associated matrix metalloproteinase activity. Cancer Metastasis Rev 2014;33(4):1043–1057.
- Dreymueller D, Ludwig A. Considerations on inhibition approaches for proinflammatory functions of ADAM proteases. Platelets 2017;28(4):354–361.
- Au AE, Josefsson EC. Regulation of platelet membrane protein shedding in health and disease. Platelets 2017;28(4):342–353.
- Chatterjee M, Gawaz M. (2017) Clinical significance of receptor shedding-platelet GPVI as an emerging diagnostic and therapeutic tool. Platelets 2017;28(4):362–371.